Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of once-daily darunavir + ritonavir in treatment-naive HIV-1 infected adolescents
2008-004631-37Phase 2Completed
- Sponsor
- Tibotec
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darunavir in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1, sponsored by Tibotec. Primary endpoint: Confirmed virologic response at week 24. Started May 2009; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2008-004631-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004631-37.